Should university students be vaccinated against meningococcal disease in Canada?

Canadian Journal of Infectious Diseases

Volumn 15, Issue 1, 2004, Pages 25-28

  De Wals, Philippe ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cost benefit; Meningococcal disease; University; Vaccination

Indexed keywords

MENINGOCOCCUS VACCINE;

ADULT; ARTICLE; CANADA; COLLEGE STUDENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION RISK; MENINGOCOCCOSIS; QUALITY ADJUSTED LIFE YEAR; UNIVERSITY; VACCINATION;

EID: 1642411645     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/740537     Document Type: Article

References (35)

1. Harrison LH. Preventing meningococcal infection in college students. Clin Infect Dis 2000;30:648-51.
2. Kelleher JA, Raebel MA. Meningococcal vaccine use in college students. Ann Pharmacother 2002;36:1776-84.
3. Advisory Committee on Immunization Practices (ACIP). Meningococcal disease and college students. Recommendations. MMWR 2000;49:11-20.
4. National Advisory Committee on Immunization (NACI). Statement on recommended use of meningococcal vaccines. CCDR 2001;27:2-36.
5. Cartwright K. Meningococcal carriage and disease. In: Cartwright K, ed. Meningococcal Disease. Chichester: John Wiley & Sons, 1995:115-46.
6. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: Cross sectional study. BMJ 2000;320:846-9.
7. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995;273:383-9.
8. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol 1996;143:624-30.
9. Gilmore A, Jones G, Barker M, Soltanpoor N, Stuart JM. Meningococcal disease at the University of Southampton: Outbreak investigation. Epidemiol Infect 1999;123:185-92.
10. Ferson M, Young L, Hansen G, et al. Unusual cluster of mild invasive serogroup C meningococcal infection in a university college. Commun Dis Intell 1999;23:261-4.
11. Round A, Evans MR, Salmon RL, et al. Public health management of an outbreak of group C meningococcal disease in university campus residents. Eur J Public Health 2001;11:431-6.
12. Neal KR, Nguyen-Van-Tam J, Monk P, O'Brien SJ, Stuart J, Ramsay M. Invasive meningococcal disease among university undergraduates: Association with universities providing relatively large amounts of catered hall accommodation. Epidemiol Infect 1999;122:351-7.
13. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 2001;286:688-93.
14. Tyrrell GJ, Chui L, Johnson M, et al. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002;8:519-21.
15. Bigham M, Trepanier MJ, Dobson S. Statistics and Reports: Meningococcal Disease in British Columbia. 2001 Summary. Vancouver: British Columbia Centre for Disease Control, 2002.
16. Bureau de surveillance épidémiologique (BSE). Épidémiologie des infections invasives à méningocoque, année 2001. Flash Méningo 2001;1:1-6.
17. Harrison LH, Dwyer DM, Maples CT, Billman L. Risk of meningococcal infection in college students. JAMA 1999;281:1906-10.
18. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis 2001;33:737-9.
19. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994;169:847-52.
20. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002;51:717-22.
21. De Wals P, Hung Nguyen V, Erickson LJ, Guay M, Drapeau J, St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine. (In press)
22. Beutels P. Economic evaluation of vaccination programmes in humans. Universiteit Antwerpen, Faculteit Geneeskunde, Vakgroep Epidemiologie en sociale Geneeskunde, Antwerpen, Belgium: 2002.
23. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
24. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ 1993;148:927-9.
25. Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health 1995;85:843-5.
26. Scott RD, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for meningococcal disease. Am J Prev Med 2002;23:98-105.
27. Lakshman R, Burkinshaw R, Choo S, Finn A. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults. Vaccine 2002;3778-82.
28. Statistics Canada. Life tables, Canada and Provinces 1990-1992. Catalogue 84-537 Occasional. Ottawa: 1996.
29. Erickson P, Wilson RW, Shannon I. Years of healthy life. Statistical Note Number 7. Hyattsville: National Centre for Health Statistics, 1995.
30. Statistics Canada. Gains moyens selon le sexe et le regime de travail, 2000. 〈www.statcan.ca/francais/Pgdb/labor01a_f.htm〉 (Version current at February 6, 2004).
31. De Wals P, Erickson L. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 2002;20:2840-4.
32. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998;26:1159-64.
33. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull WHO 1971;45:279-82.
34. Centre for Infectious Disease Prevention and Control (CIDPC). Immunization Program Options for New Candidate Vaccines: Varicella, Conjugate Pneumococcal, Conjugate Meningococcal, Acellular Pertussis (TdaP). Ottawa: Health Canada, 2002.
35. Gold MR, Siegel JE, Russet LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.